Hartford Investment Management Co. Sells 247 Shares of Moderna, Inc. (NASDAQ:MRNA)

Hartford Investment Management Co. trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 1.2% in the 3rd quarter, Holdings Channel reports. The fund owned 21,115 shares of the company’s stock after selling 247 shares during the quarter. Hartford Investment Management Co.’s holdings in Moderna were worth $1,411,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Mayfair Advisory Group LLC grew its position in Moderna by 6.0% during the first quarter. Mayfair Advisory Group LLC now owns 2,164 shares of the company’s stock worth $231,000 after buying an additional 122 shares in the last quarter. Little House Capital LLC acquired a new stake in shares of Moderna during the 1st quarter worth approximately $329,000. Quattro Financial Advisors LLC increased its position in shares of Moderna by 87,879.8% during the first quarter. Quattro Financial Advisors LLC now owns 87,100 shares of the company’s stock valued at $9,281,000 after purchasing an additional 87,001 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Moderna by 42.9% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after purchasing an additional 463,960 shares during the period. Finally, Lake Street Private Wealth LLC acquired a new position in shares of Moderna in the first quarter valued at $239,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Up 0.5 %

NASDAQ:MRNA opened at $53.09 on Friday. The company has a market cap of $20.41 billion, a price-to-earnings ratio of -3.45 and a beta of 1.66. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The stock’s fifty day moving average price is $67.68 and its two-hundred day moving average price is $102.84. Moderna, Inc. has a 52-week low of $52.26 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($3.62) earnings per share. On average, analysts anticipate that Moderna, Inc. will post -9.94 EPS for the current year.

Insider Activity

In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Moderna news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,184 shares of company stock valued at $2,037,931. 15.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MRNA. Piper Sandler decreased their price target on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, September 13th. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Finally, Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $94.65.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.